Small-molecule PAD inhibitors are regarded as promising drug candidates for treatment of RA, and ongoing investigations aim at applying them to other diseases where citrullination may play a role, such as inflammatory bowel disease, multiple sclerosis, and systemic lupus erythematosus. This evidence concerns the gene PADI4 and inflammatory bowel disease.